Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease ...

Mirum Pharmaceuticals acquires Bluejay Therapeutics, focusing on brelovitug for chronic hepatitis delta virus (HDV), a severe ...

The delta variant of SARS-CoV-2, the virus that causes COVID-19, has been making headlines as it has quickly become the most prevalent strain in America. But other variants of the virus are still out ...

The fast-spreading delta variant of the coronavirus has been gaining traction worldwide since it was first detected in India. It’s a version of the coronavirus that has been found in more than 80 ...

Prior COVID-19 vaccination did not stop the immune system from mounting a protective response to the delta and omicron strains, though new mutation-specific antibody production dipped slightly, ...

Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...

Findings showed 100% of participants taking the tobevibart and elebsiran combination achieved an undetectable HDV RNA at week 24 that was sustained through week 60. The Food and Drug Administration ...

Share on Pinterest Someone waits in line for a vaccination outside a mass vaccination center on August 23, 2021. Lisa Maree Williams/Getty Images The COVID-19 Infection Survey regularly tests a random ...

– Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented – Vir Biotechnology to ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) ...